The doylestown algorithm

A test to improve the performance of afp in the detection of hepatocellular carcinoma

Mengjun Wang, Karthik Devarajan, Amit G. Singal, Jorge A. Marrero, Jianliang Dai, Ziding Feng, Jo Ann S Rinaudo, Sudhir Srivastava, Alison Evans, Hie Won Hann, Yinzhi Lai, Hushan Yang, Timothy M. Block, Anand Mehta

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Biomarkers for the early diagnosis of hepatocellular carcinoma (HCC) are needed to decrease mortality from this cancer. However, as new biomarkers have been slow to be brought to clinical practice, we have developed a diagnostic algorithm that utilizes commonly used clinical measurements in those at risk of developing HCC. Briefly, as a-fetoprotein (AFP) is routinely used, an algorithm that incorporated AFP values along with four other clinical factors was developed. Discovery analysis was performed on electronic data from patients who had liver disease (cirrhosis) alone or HCC in the background of cirrhosis. The discovery set consisted of 360 patients from two independent locations. A logistic regression algorithm was developed that incorporated log-transformed AFP values with age, gender, alkaline phosphatase, and alanine aminotransferase levels. We define this as the Doylestown algorithm. In the discovery set, the Doylestown algorithm improved the overall performance of AFP by 10%. In subsequent external validation in over 2,700 patients from three independent sites, the Doylestown algorithm improved detection of HCC as compared with AFP alone by 4% to 20%. In addition, at a fixed specificity of 95%, the Doylestown algorithm improved the detection of HCC as compared with AFP alone by 2% to 20%. In conclusion, the Doylestown algorithm consolidates clinical laboratory values, with age and gender, which are each individually associated with HCC risk, into a single value that can be used for HCC risk assessment. As such, it should be applicable and useful to the medical community that manages those at risk for developing HCC.

Original languageEnglish (US)
Pages (from-to)172-179
Number of pages8
JournalCancer Prevention Research
Volume9
Issue number2
DOIs
StatePublished - Feb 1 2016

Fingerprint

Fetal Proteins
Hepatocellular Carcinoma
Biomarkers
Alanine Transaminase
Liver Cirrhosis
Alkaline Phosphatase
Liver Diseases
Early Diagnosis
Fibrosis
Logistic Models
Mortality
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

The doylestown algorithm : A test to improve the performance of afp in the detection of hepatocellular carcinoma. / Wang, Mengjun; Devarajan, Karthik; Singal, Amit G.; Marrero, Jorge A.; Dai, Jianliang; Feng, Ziding; Rinaudo, Jo Ann S; Srivastava, Sudhir; Evans, Alison; Hann, Hie Won; Lai, Yinzhi; Yang, Hushan; Block, Timothy M.; Mehta, Anand.

In: Cancer Prevention Research, Vol. 9, No. 2, 01.02.2016, p. 172-179.

Research output: Contribution to journalArticle

Wang, M, Devarajan, K, Singal, AG, Marrero, JA, Dai, J, Feng, Z, Rinaudo, JAS, Srivastava, S, Evans, A, Hann, HW, Lai, Y, Yang, H, Block, TM & Mehta, A 2016, 'The doylestown algorithm: A test to improve the performance of afp in the detection of hepatocellular carcinoma', Cancer Prevention Research, vol. 9, no. 2, pp. 172-179. https://doi.org/10.1158/1940-6207.CAPR-15-0186
Wang, Mengjun ; Devarajan, Karthik ; Singal, Amit G. ; Marrero, Jorge A. ; Dai, Jianliang ; Feng, Ziding ; Rinaudo, Jo Ann S ; Srivastava, Sudhir ; Evans, Alison ; Hann, Hie Won ; Lai, Yinzhi ; Yang, Hushan ; Block, Timothy M. ; Mehta, Anand. / The doylestown algorithm : A test to improve the performance of afp in the detection of hepatocellular carcinoma. In: Cancer Prevention Research. 2016 ; Vol. 9, No. 2. pp. 172-179.
@article{b4fe24b8492445978c7dffbc131d2dd8,
title = "The doylestown algorithm: A test to improve the performance of afp in the detection of hepatocellular carcinoma",
abstract = "Biomarkers for the early diagnosis of hepatocellular carcinoma (HCC) are needed to decrease mortality from this cancer. However, as new biomarkers have been slow to be brought to clinical practice, we have developed a diagnostic algorithm that utilizes commonly used clinical measurements in those at risk of developing HCC. Briefly, as a-fetoprotein (AFP) is routinely used, an algorithm that incorporated AFP values along with four other clinical factors was developed. Discovery analysis was performed on electronic data from patients who had liver disease (cirrhosis) alone or HCC in the background of cirrhosis. The discovery set consisted of 360 patients from two independent locations. A logistic regression algorithm was developed that incorporated log-transformed AFP values with age, gender, alkaline phosphatase, and alanine aminotransferase levels. We define this as the Doylestown algorithm. In the discovery set, the Doylestown algorithm improved the overall performance of AFP by 10{\%}. In subsequent external validation in over 2,700 patients from three independent sites, the Doylestown algorithm improved detection of HCC as compared with AFP alone by 4{\%} to 20{\%}. In addition, at a fixed specificity of 95{\%}, the Doylestown algorithm improved the detection of HCC as compared with AFP alone by 2{\%} to 20{\%}. In conclusion, the Doylestown algorithm consolidates clinical laboratory values, with age and gender, which are each individually associated with HCC risk, into a single value that can be used for HCC risk assessment. As such, it should be applicable and useful to the medical community that manages those at risk for developing HCC.",
author = "Mengjun Wang and Karthik Devarajan and Singal, {Amit G.} and Marrero, {Jorge A.} and Jianliang Dai and Ziding Feng and Rinaudo, {Jo Ann S} and Sudhir Srivastava and Alison Evans and Hann, {Hie Won} and Yinzhi Lai and Hushan Yang and Block, {Timothy M.} and Anand Mehta",
year = "2016",
month = "2",
day = "1",
doi = "10.1158/1940-6207.CAPR-15-0186",
language = "English (US)",
volume = "9",
pages = "172--179",
journal = "Cancer Prevention Research",
issn = "1940-6207",
publisher = "American Association for Cancer Research Inc.",
number = "2",

}

TY - JOUR

T1 - The doylestown algorithm

T2 - A test to improve the performance of afp in the detection of hepatocellular carcinoma

AU - Wang, Mengjun

AU - Devarajan, Karthik

AU - Singal, Amit G.

AU - Marrero, Jorge A.

AU - Dai, Jianliang

AU - Feng, Ziding

AU - Rinaudo, Jo Ann S

AU - Srivastava, Sudhir

AU - Evans, Alison

AU - Hann, Hie Won

AU - Lai, Yinzhi

AU - Yang, Hushan

AU - Block, Timothy M.

AU - Mehta, Anand

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Biomarkers for the early diagnosis of hepatocellular carcinoma (HCC) are needed to decrease mortality from this cancer. However, as new biomarkers have been slow to be brought to clinical practice, we have developed a diagnostic algorithm that utilizes commonly used clinical measurements in those at risk of developing HCC. Briefly, as a-fetoprotein (AFP) is routinely used, an algorithm that incorporated AFP values along with four other clinical factors was developed. Discovery analysis was performed on electronic data from patients who had liver disease (cirrhosis) alone or HCC in the background of cirrhosis. The discovery set consisted of 360 patients from two independent locations. A logistic regression algorithm was developed that incorporated log-transformed AFP values with age, gender, alkaline phosphatase, and alanine aminotransferase levels. We define this as the Doylestown algorithm. In the discovery set, the Doylestown algorithm improved the overall performance of AFP by 10%. In subsequent external validation in over 2,700 patients from three independent sites, the Doylestown algorithm improved detection of HCC as compared with AFP alone by 4% to 20%. In addition, at a fixed specificity of 95%, the Doylestown algorithm improved the detection of HCC as compared with AFP alone by 2% to 20%. In conclusion, the Doylestown algorithm consolidates clinical laboratory values, with age and gender, which are each individually associated with HCC risk, into a single value that can be used for HCC risk assessment. As such, it should be applicable and useful to the medical community that manages those at risk for developing HCC.

AB - Biomarkers for the early diagnosis of hepatocellular carcinoma (HCC) are needed to decrease mortality from this cancer. However, as new biomarkers have been slow to be brought to clinical practice, we have developed a diagnostic algorithm that utilizes commonly used clinical measurements in those at risk of developing HCC. Briefly, as a-fetoprotein (AFP) is routinely used, an algorithm that incorporated AFP values along with four other clinical factors was developed. Discovery analysis was performed on electronic data from patients who had liver disease (cirrhosis) alone or HCC in the background of cirrhosis. The discovery set consisted of 360 patients from two independent locations. A logistic regression algorithm was developed that incorporated log-transformed AFP values with age, gender, alkaline phosphatase, and alanine aminotransferase levels. We define this as the Doylestown algorithm. In the discovery set, the Doylestown algorithm improved the overall performance of AFP by 10%. In subsequent external validation in over 2,700 patients from three independent sites, the Doylestown algorithm improved detection of HCC as compared with AFP alone by 4% to 20%. In addition, at a fixed specificity of 95%, the Doylestown algorithm improved the detection of HCC as compared with AFP alone by 2% to 20%. In conclusion, the Doylestown algorithm consolidates clinical laboratory values, with age and gender, which are each individually associated with HCC risk, into a single value that can be used for HCC risk assessment. As such, it should be applicable and useful to the medical community that manages those at risk for developing HCC.

UR - http://www.scopus.com/inward/record.url?scp=84957971663&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84957971663&partnerID=8YFLogxK

U2 - 10.1158/1940-6207.CAPR-15-0186

DO - 10.1158/1940-6207.CAPR-15-0186

M3 - Article

VL - 9

SP - 172

EP - 179

JO - Cancer Prevention Research

JF - Cancer Prevention Research

SN - 1940-6207

IS - 2

ER -